TheFly.com
TENX
Tenax Therapeutics
$
()
Tenax Therapeutics reports Q2 EPS ($1.83), consensus ($1.98)
Tenax announces plans to accelerate oral levosimendan Phase 3 program
Tenax Therapeutics announces oversubscribed $100M private placement
Tenax Therapeutics reports Q1 EPS ($3.12) vs. ($12.10) last year
Tenax Therapeutics announces new U.S. patent covering use of levosimendan
Tenax Therapeutics reports FY23 EPS ($31.04) vs ($600.71) last year
Tenax negotiates global levosimendan rights, says Roth MKM
Tenax announces global license amendment, expands rights to levosimendan
Tenax Therapeutics prices 1.6M shares at $5.65 in public offering
Tenax Therapeutics enrolls first patient in Phase 3 study of TNX-103
Tenax Therapeutics trading resumes
Copyright ©1998-2024 Thefly.com LLC
